Use of circulating tumor DNA to guide adjuvant treatment planning for patients with resectable colon cancer led to fewer patients receiving chemotherapy while maintaining outcomes, according to the DYNAMICS study.
CtDNA Effectively Detects When Adjuvant Chemo Is Avoidable in Stage II Colon Cancers
Posted in biotech/medical